Skip to main content

Skin Roughness

3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Menarini
MenariniGermany - Dresden
1 program
1
KinerasePhase 41 trial
Active Trials
NCT01885091Completed100
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
VYC-12 HA injectable gelPhase 41 trial
Active Trials
NCT02877069Completed134Est. Oct 2016
Krystal Biotech
Krystal BiotechPA - Pittsburgh
1 program
1
KB301Phase 11 trial
Active Trials
NCT04540900Active Not Recruiting85Est. May 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AbbVieVYC-12 HA injectable gel
MenariniKinerase
Krystal BiotechKB301

Clinical Trials (3)

Total enrollment: 319 patients across 3 trials

NCT02877069AbbVieVYC-12 HA injectable gel

Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment of Superficial Cutaneous Depressions

Start: Sep 2015Est. completion: Oct 2016134 patients
Phase 4Completed
NCT01885091MenariniKinerase

Efficacy and Safety Study of Kinerase® for Treatment of Cutaneous Facial Photodamage

Start: Dec 2012100 patients
Phase 4Completed
NCT04540900Krystal BiotechKB301

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

Start: Oct 2020Est. completion: May 202985 patients
Phase 1Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.